Substantiation of the choice of components for a combined drug used for the treatment of type 2 diabetes mellitus

K. N. Toraiev, A. S. Nemchenko, N. A. Tsubanova, O. M. Bezchasniuk, L. V. Yevsieieva

Abstract


Diabetes mellitus (DM) is one of the most common non-communicable diseases in the world. As evidenced by the UN resolution, DM is recognized as one of the most threatening diseases in the world. At present there are more than 382 million people with DM. In the EU almost 4-6 % of the population suffers from type 2 diabetes mellitus (DM 2). It should be noted that this disease occurs with an extremely high risk of complications, which lead to disability, morbidity and mortality of patients in this category.

Aim. To substantiate the choice of components for introduction of a combined drug used for the treatment of DM 2.

Materials and methods. The results of meta-analyses concerning medical information of the drug use when treating DM 2 were analyzed.

Results and discussion. The results of the comparative studies of antidiabetic drugs were generalized; the expediency and rationality of the use of metformin as a drug with the proven efficacy and safety when treating DM 2 was revealed.

Conclusions. The authors have proposed and substantiated the effectiveness of a new antidiabetic composition with two API: metformin (400 mg) and benfotiamine (20 mg). The new composition with metformin and benfotiamine has been confirmed by the pharmacological studies as a highly effective antidiabetic agent with a pronounced antioxidant effect and the ability to restore cellular energy deficiency.


Keywords


combined antidiabetic drug; metformin; benfotiamine; algorithm of the primary development; pharmacological studies

Full Text:

PDF

References


Балаболкин, М. И. Лечение сахарного диабета и его осложнений (руководство для врачей) / М. И. Балаболкин, Е. М. Клебанова, В. М. Креминская. – М. : Медицина, 2005. – 511 с.

Программа ВОЗ по діабету [Електронний ресурс] // ВОЗ. – Режим доступу : http://www.who.int/diabetes/ru.

Holst, J. J. The physiology and pharmacology of incretins in type 2 diabetes mellitus / Jens J. Holst // Diabetes, Obesity and Metabolism. – 2008. – Vol. 10. – Р. 14–21. doi : 10.1111/j.1463–1326.2008.00920.x.

Розробка алгоритму створення комбінованого лікарського засобу / К. Н. Тораєв, А. С. Немченко, Л. В. Євсєєва, Ю. І. Губін // Управління, економіка та забезпечення якості в фармації. – 2016. – № 3. – С. 9–15.

Древаль, А. В. Роль сахароснижающих таблетированных препаратов в лечении сахарного диабета 2 типа / А. В. Древаль, И. В. Мисникова // Рос. мед. журн. – 2005. – Т. 13, № 6. – С. 332–334.

Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients with Type 2 Diabetes Inadequately Controlled with Metformin / E. Bosi, R. P. Camisasca, C. Collober et al. // Diabetes Care. – 2007. – Vol. 30, Issue 4. – Р. 890–895. doi : 10.2337/dc06–1732.

Dipeptidyl peptidase–4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta–analysis // BMJ. – 2012. doi : 10.1136/bmj.e1369.

Even more about diabetes. Dollars and sensible therapeutics [Internet]. – Available at : http://www.slideshare.net/ARHGrandRounds/abbotsford–feb–26–2014.

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study / T. K. Schramm, G. H. Gislason, A. Vaag et al. // Eur. Heart J. – 2011. – Vol. 32, Issue 15. – P. 1900–1908. doi : 10.1093/eurheartj/ehr077.

Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug–naive patients with type 2 diabetes / A. Schweizer [et al.] // Diabet Med. – 2007. – Vol. 24, Issue 9. – Р. 955–961. doi : 10.1111/j.1464–5491.2007.02191.x.

Діабетичні нейропатії / О. О. Сергієнко, А. С. Єфімов, Д. А. Єфімов, Ю. Я. Кривко ; НАМН України, ЛНМУ ім. Данила Галицького, Інститут ендокринології та ОР ім. В. П. Комісаренка НАМН України. – Львів; К., 2004. – С. 24–45.

Гурьева, И. В. Терапевтические возможности бенфотиамина / И. В. Гурьева // Фарматека. Эндокринология. – 2010. – № 16 (210). – С. 26–30.

Верткин, А. Л. Преимущества бенфотиаминсодержащих препаратов в лечении диабетической полинейропатии / А. Л. Верткин, В. В. Городецкий // Фарматека. – 2005. – № 10.– С. 1–6.

Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy / H. P. Hammes, X. Du, D. Edelstein et al. // Nature Med. – 2003. – Vol. 9. – P. 1–6.

Майоров, А. Ю. Современные сахароснижающие средства в лечении сахарного диабета 2 типа / А. Ю. Майоров, И. В. Науменкова // Рус. мед. журн. – 2001. – Т. 9, № 24. – С. 1105–1111.

Эндокринология: национальное руководство / под ред. И. И. Дедова, Г. А. Мельниченко. – М. : ГЭОТАР–Медиа, 2012. – 1072 с.

Зилов, А. В. Метформин – 50 лет в клинической практике / А. В. Зилов, А. Л. Терехова // Лечащий врач. – 2008. – № 3. – С. 15–39.

Larson, N. F. Metformin More Effective if Initiated Soon After Diabetes Diagnosis / N. F. Larson // Diabetes Care. – 2010. – Р. 501–506.

Доклінічні дослідження лікарських засобів : метод. рек. / за ред. О. В. Стефанова. – К. : Авіценна, 2001. – С. 396–404.

Грицюк, М. І. Порівняльна характеристика експериментальних моделей цукрового діабету / М. І. Грицюк, Т. М. Бойчук, О. І. Петришев // Світ медицини та біології. – 2014. – № 2 (44). – С. 199–203.

Мкртумян, А. М. Метформин с пролонгированным высвобождением (Глюкофаж Лонг) – высокоэффективный и безопасный препарат первой линии в лечении сахарного диабета 2 типа / А. М. Мкртумян // Рус. мед. журн. Эндокринол. – 2011. – № 13. – С. 838. – Режим доступу : http://www.rmj.ru/articles_7735.htm.

Riddle, M. C. Combined Therapy with Insulin Plus Oral Agents. Is there Any Advantage [Internet] / M. C. Riddle. – Available at : http://www.codhy.com/berlin/Uploads/assets/pptriddel.pdf

High–dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin–induced diabetes mellitus / A. F. Ceylan–Isik, S. Wu, Q. Li et al. // J. Appl. Phisiol. – 2006. – Vol. 100, Issue 1. – P. 150–156. doi : 10.1152/japplphysiol.00988.2005.


GOST Style Citations


1.  Balabolkin, M. I., Klebanov, E. M., Kreminskaya, V. M. (2005). Lechenie sakharnogo diabeta i ego oslozhnenii ( rukovodstvo dlia vrachei). Moscow: Medicine, 511.

2.  Programma VOZ po diabetu. Available at: www.who.int/diabetes/ru.

3.  Holst, J. J. (2008). The physiology and pharmacology of incretins in type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 10, 14–21. doi: 10.1111/j.1463–1326.2008.00920.x.

4.  Toraiev, K. N., Nemchenko, A. S., Yevsieieva, L. V., Hubin, Yu. I.(2016). Upravlinnia, economika ta zabezpechennia yakosti v farmatsii, 3, 9–15.

5.  Dreval, A. V., Misnikova, I.V. (2005). Russkii meditcinskii zhurnal, 13 (6), 332–334.

6.  Bosi, E., Camisasca, R. P., Collober, C., Rochotte, E., Garber, A. J. (2007). Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin. Diabetes Care, 30 (4), 890–895. doi: 10.2337/dc06–1732.

7.  Dipeptidyl peptidase–4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta–analysis (2012). BMJ. doi: 10.1136/bmj.e1369.

8.  Even more about diabetes. Dollars and sensible therapeutics. Available at: http://www.slideshare.net/ARHGrandRounds/abbotsford–feb–26–2014.

9. Schramm, T. K., Gislason, G. H., Vaag, A., Rasmussen, J. N., Folke, F., Hansen, M. L., Torp–Pedersen, C. (2011). Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European Heart Journal, 32 (15), 1900–1908. doi: 10.1093/eurheartj/ehr077.

10.       Schweizer, A., Couturier, A., Foley, J. E., Dejager, S. (2007). Comparison between vildagliptin and metformin to sustain reductions in HbA1cover 1 year in drug–naïve patients with Type 2 diabetes. Diabetic Medicine, 24 (9), 955–961. doi: 10.1111/j.1464–5491.2007.02191.x.

11.       Serhiienko, O. O., Yefimov, A. S., Yefimov, D. A., Kryvko, Yu. Ya. (2004). Diabetichni neiropatii. Lviv; Kyiv, 24–45.

12.       Gureva, I.V. (2010). Farmateka. Endokrinologia, 16 (210), 26–30.

13.       Vertkin, A. L., Gorodetskyi, V. V. (2005). Farmateka, 10, 1–6.

14.       Hammes, H. P., Du, X., Edelstein, D. et al. (2003). Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Med, 9, 1–6.

15.       Maiorov, A. Yu., Naumenkova, I.V. (2001). Russkii meditcinskii zhurnal, 9 (24), 1105–1111.

16.       Dedov, I., Melnichenko, H. A. (2012). Endokrinologiia: natcionalnoe rukovodstvo.Moscow: GEOTAR–Media, 1072.

17.       Zilov, A. V., Terekhova A. L. (2008). Lechashchii vrach, 3, 15–39.

18.       Larson, N. F. (2010). Metformin More Effective if Initiated Soon After Diabetes Diagnosis. Diabetes Care, 501—506.

19.       Stefanova, A. V. (2001). Doclinichni doslidzhennia likarskikh zasobiv. Kyiv: Avicenna, 396–404.

20.       Hrytsiuk, M. I., Boihuk, T. M., Petryshev, A. I. (2014). Svit medytsyny ta bilogii, 2 (44), 199–203.

21.       Mkrtumian, A. M. (2011). Russkii meditcinskii zhurnal. Endokrinolohiia, 13, 838. Available at: http://www.rmj.ru/articles_7735.htm.

22.       Riddle, M. C. Combined Therapy with Insulin Plus Oral Agents. Is there Any Advantage. Available at: http://www.codhy.com/berlin/Uploads/assets/pptriddel.pdf.

23.       Ceylan–Isik, A. F. (2006). High–dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin–induced diabetes mellitus. Journal of Applied Physiology, 100 (1), 150–156. doi: 10.1152/japplphysiol.00988.2005.





DOI: https://doi.org/10.24959/nphj.17.2156

Abbreviated key title: Vìsn. farm.

ISSN 2415-8844 (Online), ISSN 1562-7241 (Print)